journal article·2022-12-31Open access

Co-delivery of STAT3 siRNA and methotrexate in breast cancer cells

Zahra Shakeran, Jaleh Varshosaz, Mehrnaz Keyhanfar, Hossein Mohammad-Beigi, Karim Rahimi, Duncan S. Sutherland

Abstract

Co-delivery of anticancer drugs and biologics can provide synergetic effects and outperform single delivery therapies. Here, a nanoparticle (NP) system for co-delivery of methotrexate (MTX) and STAT3 siRNA has been developed and tested in vitro. Mesoporous silica nanoparticles (MSNs) were functionalized with chitosan (ch) by covalent grafting mediated by aminopropyl triethoxysilane (APTES) via glutaraldehyde as the linker. Co-delivery of MTX and STAT3 siRNA to MCF7 cells was demonstrated in cells by flow cytometric analysis and confocal laser scanning fluorescence microscopy for use in breast cancer treatment. MTX either competitively inhibits the dihydrofolate reductase (DHFR) receptor or suppresses the STAT3 metabolic pathway. STAT3 protein plays an essential role in cell division, proliferation and survival. Reduction of the protein by both MTX and STAT3 siRNA, achieved by chMSNs, significantly decreased the viability of breast cancer cells compared to single treatments alone. Cellular uptake of modified NPs was increased over time when additional free MTX was added implicating the DHFR receptor in uptake. In addition, protein corona compositions coated the NPs outer surface, were different between the NPs with and without drug potentially modulating cellular uptake. This study is the first report on co-delivery of MTX and STAT3 siRNA by chitosan modified MSNs.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Biotechnology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran

iNANO Center, Aarhus University, Aarhus C, Denmark

Department of Pharmaceutics, School of Pharmacy and Novel Drug Delivery Systems Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Department of Biotechnology and Biomedicine, Technical University of Denmark, Kgs. Lyngby, Denmark

Department of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark

Funding

University of Isfahan · Biotechnology Development Council of Iran · DFF · Danish Council for Independent Research

References (50)

Show source-provided references
1. 10.3322/caac.2133210.3322/caac.21332 ↗
2. 10.1002/adma.20130123210.1002/adma.201301232 ↗
3. 10.1039/C4TB01533A10.1039/C4TB01533A ↗
4. 10.1016/j.nano.2014.09.01410.1016/j.nano.2014.09.014 ↗
5. 10.1016/j.jconrel.2015.09.05710.1016/j.jconrel.2015.09.057 ↗
6. 10.1021/mp400596v10.1021/mp400596v ↗
7. 10.1021/tx300166u10.1021/tx300166u ↗
8. 10.1002/smll.20090062110.1002/smll.200900621 ↗
9. 10.1021/acsami.6b0995010.1021/acsami.6b09950 ↗
10. 10.1080/17425255.2017.123019810.1080/17425255.2017.1230198 ↗
11. 10.1021/acs.molpharmaceut.9b0035910.1021/acs.molpharmaceut.9b00359 ↗
12. 10.1016/j.trsl.2012.08.00510.1016/j.trsl.2012.08.005 ↗
13. 10.1016/S0925-4439(02)00079-010.1016/S0925-4439(02)00079-0 ↗
14. 10.1038/nm124910.1038/nm1249 ↗
15. 10.1111/j.1745-7254.2005.00053.x10.1111/j.1745-7254.2005.00053.x ↗
16. 10.4155/tde-2016-004510.4155/tde-2016-0045 ↗
17. 10.1021/nn304406610.1021/nn3044066 ↗
18. 10.1016/j.micromeso.2009.11.01510.1016/j.micromeso.2009.11.015 ↗
19. 10.1021/cm021310e10.1021/cm021310e ↗
20. 10.1021/jp103982a10.1021/jp103982a ↗
21. 10.1016/j.biomaterials.2012.10.07210.1016/j.biomaterials.2012.10.072 ↗
22. 10.1021/am508219g10.1021/am508219g ↗
23. 10.1002/jbm.a.3041010.1002/jbm.a.30410 ↗
24. 10.1039/C6DT03783F10.1039/C6DT03783F ↗
25. 10.3390/chemengineering202002410.3390/chemengineering2020024 ↗
26. 10.1016/j.colsurfb.2017.04.00210.1016/j.colsurfb.2017.04.002 ↗
27. 10.1002/smll.20090235510.1002/smll.200902355 ↗
28. 10.3109/10717544.2013.83871410.3109/10717544.2013.838714 ↗
29. 10.1016/j.msec.2020.11152610.1016/j.msec.2020.111526 ↗
30. 10.1021/nn200809t10.1021/nn200809t ↗
31. 10.1016/j.physe.2011.10.01510.1016/j.physe.2011.10.015 ↗
32. 10.1021/nn100690m10.1021/nn100690m ↗
33. 10.1038/srep4151710.1038/srep41517 ↗
34. 10.1021/ar300098610.1021/ar3000986 ↗
35. Pedraza D, Díez J, Colilla M, et al. Amine-functionalized MSNs: a new nanoantibiotic for bone infection treatment. Biomed Glass. 2018;3:1–12.
36. 10.1016/j.addr.2010.10.00810.1016/j.addr.2010.10.008 ↗
37. 10.1007/s10570-011-9632-x10.1007/s10570-011-9632-x ↗
38. 10.1021/jp102368s10.1021/jp102368s ↗
39. 10.1088/0957-4484/17/22/00110.1088/0957-4484/17/22/001 ↗
40. 10.1208/s12248-008-9073-010.1208/s12248-008-9073-0 ↗
41. Briggs L Russell W. 107. Sophora alkaloids. Part IV. The alkaloids from the seeds of the Chatham Islands species. J Chem Soc. 1942;555–556.10.1039/jr9420000555 ↗
42. 10.1016/j.toxlet.2013.04.02210.1016/j.toxlet.2013.04.022 ↗
43. 10.1080/17435390.2016.126463810.1080/17435390.2016.1264638 ↗
44. 10.1039/C5NR04726A10.1039/C5NR04726A ↗
45. 10.1039/C4RA03277B10.1039/C4RA03277B ↗
46. 10.1021/acs.biomac.5b0010810.1021/acs.biomac.5b00108 ↗
47. 10.7150/thno.826310.7150/thno.8263 ↗
48. 10.3892/mmr.2016.528610.3892/mmr.2016.5286 ↗
49. 10.1016/j.bcp.2019.11366610.1016/j.bcp.2019.113666 ↗
50. 10.1002/JLB.5RU0519-145R10.1002/JLB.5RU0519-145R ↗